A Randomized, Double-Blind, Placebo-Controlled, Phase 3 Study to Assess the Safety and Efficacy of ART-123 in Subjects With Severe Sepsis and Coagulopathy

Trial Profile

A Randomized, Double-Blind, Placebo-Controlled, Phase 3 Study to Assess the Safety and Efficacy of ART-123 in Subjects With Severe Sepsis and Coagulopathy

Active, no longer recruiting
Phase of Trial: Phase III

Latest Information Update: 02 Aug 2018

At a glance

  • Drugs Thrombomodulin alfa (Primary)
  • Indications Disseminated intravascular coagulation
  • Focus Adverse reactions; Registrational; Therapeutic Use
  • Acronyms SCARLET
  • Sponsors Asahi Kasei Pharma America Corp
  • Most Recent Events

    • 02 Aug 2018 Primary endpoint has not been met. (Primary Efficacy Outcome Measure), as per results published in an Asahi Kasei Pharma America media release.
    • 02 Aug 2018 Preliminary Results published in an Asahi Kasei Pharma America Media Release
    • 22 Mar 2018 Status changed from recruiting to active, no longer recruiting.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top